Per your message, oncs is working on dosing and safety and not efficacy.
So, what are you excited about the dosing, safety, or both? I'm glad you can point this out since this is all I'm saying. .oncs pps is reflective of the data it has, safety and dosing.
Daud has published many articles, including several on data from pre phase II.